Vanda Pharmaceuticals Inc. VNDA
Biotechnology: Pharmaceutical Preparations · IPO 2006 · data as of November 13, 2026
Vanda Pharmaceuticals Inc. (VNDA) is a healthcare company listed in the US with a market value of about $241M. In the twelve months to September 30, 2026 it had revenue of $229M and net income of -$275M, a net margin of -119.9%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -3% a year, a 5-year average ROIC of -7%.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2006. Revenue went from $50M in 2014 to $216M in 2025, growth of about 14.2% a year. It was profitable in 6 of the last 10 years in our data. Its share count rose by 3% over three years (dilution for shareholders). It spends 51% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $229M | $216M | $199M | $193M | $254M | $269M | $248M | $227M | $193M | $165M | $146M |
| Net income | -$275M | -$220M | -$19M | $3M | $6M | $33M | $23M | $116M | $25M | -$16M | -$18M |
| Free cash flow | -$140M | -$110M | -$16M | $12M | $31M | $64M | $50M | $45M | $30M | -$4M | -$10M |
| EPS (diluted) | $-4.62 | $-3.74 | $-0.33 | $0.04 | $0.11 | $0.58 | $0.42 | $2.11 | $0.48 | $-0.35 | $-0.41 |
| Net margin | -119.9% | -102.0% | -9.5% | 1.3% | 2.5% | 12.3% | 9.4% | 50.9% | 13.1% | -9.4% | -12.3% |
| ROIC | — | -35.9% | -6.1% | -2.0% | 0.7% | 6.4% | 4.3% | 4.2% | 7.8% | -10.2% | -11.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $11.50, 188% above the current price; targets range from $4.50 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-2.52 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Vanda Pharmaceuticals pay a dividend?
Not currently.
Is Vanda Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Vanda Pharmaceuticals scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.